We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads

By LabMedica International staff writers
Posted on 29 Mar 2015
Print article
The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).

Kalorama based its finding on market research and interviews with IVD manufacturers and distributors. The analysis, published in Kalorama’s report “The Market for In Vitro Diagnostic Tests In Latin America," focuses on reagents and instruments in the main countries. Brazil, Chile, Columbia, Peru and Argentina are singled out for a deeper level of analysis. Uruguay, Venezuela, Ecuador, and other nations are also considered.

“The maturation of IVD markets in developed countries has IVD companies casting their nets in developing countries where rising incomes and standards of living are anticipated to spark a new health consciousness population with growing demands for quality medical care,” said Bruce Carlson, Kalorama Information publisher, “Latin America is a key target for IVD manufacturers,” expected to give additional opportunities in the near future, at an average annual growth twice the worldwide rate.

Brazil has the number one IVD market in the Latin America. The sector is growing at good pace in Brazil, Chile, and Colombia. Due to their current political and economic situations other nations might lag behind for some time. Kalorama’s report suggests this region’s IVD market is attractive but has large challenges to overcome, about which the report provides guidance.

“One of the challenges is that each country is a world on its own: different regulations on sales, insured populations, reimbursement policies, and a number of logistic issues.” said Mr. Carlson, “That’s why we attempted to provide as much detail as possible by country.” Tailored strategies are needed for each of the countries, which vary in size, healthcare infrastructure, and affordability. Companies preparing to enter this market need to understand regulations, have dedicated bilingual personnel, and optimize post-sales costs through regional training centers.

“Marketing strategies from mature markets might end up failing in these countries,” said Mr. Carlson, “working with distributors that fully understand the region is key.” The report provides information on distributors that lead sales in each country, as well as market share tables for each featured country and for many product categories.

Related Links:

Kalorama Information
Market for In Vitro Diagnostic Tests In Latin America, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.